Welcome to our dedicated page for Sanuwave Health news (Ticker: SNWV), a resource for investors and traders seeking the latest updates and insights on Sanuwave Health stock.
SANUWAVE Health, Inc. reports company developments tied to FDA-cleared and FDA-approved directed-energy systems used in advanced wound care. The company researches, develops and commercializes non-invasive regenerative medicine technologies designed to activate biological responses for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. Its wound care portfolio includes the UltraMIST product line and related product candidates.
Recurring news includes quarterly and annual revenue updates, financial guidance, conference-call materials, medical-device commercialization activity and channel relationships for UltraMIST. Company updates also describe applications of its energy transfer technologies in wound healing, orthopedic and spine, aesthetic and cosmetic, and cardiac and endovascular conditions.
Sanuwave (NASDAQ: SNWV) reported Q1 2026 revenue of $9.6 million, up 3.1% year over year and the highest Q1 in company history. Gross margin was 77.3% versus 79.0% in Q1 2025. GAAP operating loss was $1.1 million, with net loss of $1.4 million. Adjusted EBITDA was $1.1 million.
The company sold 97 Ultramist systems, while Ultramist consumables revenue rose 15% to $6.7 million and represented 100% of revenue. Sanuwave forecasts Q2 2026 revenue of $11.1–$11.6 million (10–15% growth) and reiterates 2026 revenue guidance of $51.0–$55.0 million (16–25% growth versus 2025).
Sanuwave (NASDAQ: SNWV) will host a live conference call on May 13, 2026 at 8:30 AM ET to present Q1 2026 financial results. Telephone and webcast access are provided; replay available through May 27, 2026. Materials will be posted at the company investor website.
Dial-in numbers, conference ID, webcast link, and replay details are available for investors to listen live or on replay.
Sanuwave (NASDAQ: SNWV) reported preliminary Q1 2026 revenue of $9.6–$9.7 million, a 3–4% increase versus Q1 2025 and in line with prior guidance. Management said several good-sized deals slipped out of the quarter, and Q1 results are preliminary pending quarter-end close.
CEO noted strong practitioner interest at the SAWC conference and emphasized continued focus on Ultramist amid reimbursement headwinds.
Sanuwave (NASDAQ: SNWV) reported record quarterly and annual revenue: $13.4M in Q4 2025 (+29.7% YoY) and $44.1M for full-year 2025 (+35.0% YoY). Gross margin was 74.7% in Q4 and 77.1% for 2025. GAAP operating income was $2.0M Q4 and $4.9M for 2025. Adjusted EBITDA improved to $4.8M Q4 and $13.6M for 2025. Company guides Q1 2026 revenue of $9.6–10.3M and 2026 revenue of $51.0–55.0M (16–25% growth).
Sanuwave (NASDAQ: SNWV) will host a live conference call on March 27, 2026 at 8:30 AM ET to present Q4 and full year 2025 financial results. Telephone and instant-access webcast details, conference and replay IDs, and investor materials will be available on the company website.
Telephone dial-in, international numbers, and replay instructions are provided; a replay will be available through April 10, 2026.
Sanuwave Health (NASDAQ: SNWV) reported preliminary Q4 2025 revenue of $13.3–$13.4 million, a 29–30% increase versus Q4 2024 and the company’s highest quarterly revenue ever. Full-year 2025 revenue rose to $44.3–$44.4 million, up 36% year-over-year and a record for the company. Management said Q4 results are within prior guidance and are based on preliminary quarter-end analysis that may be adjusted during financial close. The company noted market disruption from reduced reimbursement for skin-substitutes and allografts, and said it is adding partners and sales channels while adapting its business model. Final audited results and further detail will be released with the March earnings report.
Sanuwave Health (NASDAQ: SNWV) will attend the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12 to January 15, 2026. The company offers FDA-approved next-generation wound care products and said management will be available for meetings during the conference.
Investors or parties wishing to meet should contact investors@sanuwave.com to schedule a time.
Sanuwave (NASDAQ: SNWV) announced that its UltraMIST wound-care system has been added to Healogics iSupply, the Healogics Group Purchasing Organization, making UltraMIST an option for iSupply members including Wound Care Centers, home health agencies, and skilled nursing facilities.
Sanuwave said it plans to roll out the UltraMIST system to initial iSupply locations by the end of 2025. The companies described the arrangement as a collaboration intended to provide a cost-saving, FDA-approved wound healing option to Healogics members.
Sanuwave (NASDAQ: SNWV) reported Q3 FY2025 revenue of $11.5M, up 22% year‑over‑year and a sequential increase of 13%, marking the company's highest quarterly revenue on record.
Q3 gross margin was 77.9%. GAAP operating income was $1.5M after $1.4M of stock‑based compensation. Net income was $10.3M, driven by a $6.1M non‑cash gain on derivative liabilities and a $5.0M patent sale. Adjusted EBITDA was $3.5M.
The company forecasted Q4 2025 revenue $13–$14M and full‑year revenue of $44–$45M (a 35–39% increase vs 2024).
Sanuwave (NASDAQ: SNWV) will host a live conference call to present its Q3 2025 financial results on Friday, November 7, 2025 at 8:30 AM ET. Telephone access: Toll-Free 1-800-274-8461 or International 1-203-518-9814 with Conference ID SANUWAVE. Instant telephone access is available via the webcast link. Materials will be posted at www.sanuwave.com/investors. A replay will be available through November 28, 2025 via Toll-Free 1-844-512-2921 or 1-412-317-6671 using Replay Access ID 11160405.